Germany · Delayed Price · Currency is EUR TAKKT AG Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw a 6.6% organic sales decline amid weak demand, but structural improvements and cost savings strengthened resilience. 2026 guidance anticipates organic sales between -7% and +3%, with a focus on margin recovery and positive free cash flow.
-
2025 saw sales and EBITDA decline amid volatile markets, with significant goodwill impairments and a proposed dividend suspension. Operational improvements and commercial initiatives are gaining traction, and a gradual return to growth is expected in 2026.
-
Q3 saw sales decline 9% year-over-year and an adjusted EBITDA margin of 4.3%, with positive free cash flow and ongoing cost-saving measures. Full-year guidance was narrowed, with organic growth expected between -8% and -4% and continued margin pressure from tariffs and market headwinds.
-
Q2 sales declined 7.7% year-over-year with organic growth at -5.7%, and adjusted EBITDA margin fell to 3.6%. Cost and cash management measures are being accelerated, with a full-year outlook for organic growth between -9% and -2% and adjusted EBITDA margin of 4% to 6%.
-
Q1 results showed stabilized top-line and improved gross margin sequentially, but profitability and cash flow were impacted by lower sales and inventory investments. Full-year guidance is maintained, with recovery expected in H2, contingent on tariff resolution.
-
TAKKT Forward strategy centers on Industrial Packaging as the core growth driver, with clear financial targets for 2025 and 2028, including EBITDA margin improvements and strong cash generation. Major investments in digital transformation, sustainability, and operational efficiency support a customer-centric, omnichannel approach.
Fiscal Year 2024
-
2024 results reached the upper end of guidance, with strong cash flow but a 15.4% organic sales decline and lower profitability due to internal challenges and weak markets. Divisional performance was down across the board, but cost management and cash conversion improved, supporting a stable dividend.
-
Q3 saw a 14% year-over-year sales decline but improved sequentially, with profitability still below targets despite cost savings and operational fixes. Internal challenges and weak markets persist, leading to a lowered full-year outlook and ongoing strategic review.
-
H1 2024 saw a sharp sales and profit decline due to weak markets and major internal disruptions, especially in FoodService and from the Ratioform brand merger. Leadership transition and operational fixes are underway, with gradual improvement expected in H2 driven by internal measures, not market recovery.